Glargine U300 Hospital Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

March 22, 2019

Study Completion Date

March 22, 2019

Conditions
Type 2 Diabetes
Interventions
DRUG

Glargine U300

Glargine U300 is a new generation long-acting insulin.

DRUG

Glargine U100

Glargine U100 is a long-acting insulin.

DRUG

Glulisine Insulin

Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.

Trial Locations (4)

30303

Grady Memorial Hospital, Atlanta

30322

Emory University, Atlanta

44195

Cleveland Clinic, Cleveland

55415

Hennepin County Medical Center, Minneapolis

All Listed Sponsors
lead

Emory University

OTHER

NCT03013985 - Glargine U300 Hospital Trial | Biotech Hunter | Biotech Hunter